Literature DB >> 16537292

Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.

Anthony P Hall1, F Russell Westwood, Peter F Wadsworth.   

Abstract

The formation of new blood vessels from a pre-existing vascular bed, termed "angiogenesis," is of critical importance for the growth and development of the animal since it is required for the growth of the skeleton during endochondral ossification, development and cycling of the corpus luteum and uterus, and for the repair of tissues during wound healing. "Vasculogenesis," the de novo formation of blood vessels is also important for the proper function and development of the vascular system in the embryo. New blood vessel formation is a prominent feature and permissive factor in the relentless progression of many human diseases, one of the most important examples of which is neoplasia. It is for this reason that angiogenesis is considered to be one of the hallmarks of cancer. The development of new classes of drugs that inhibit the growth and proper functioning of new blood vessels in vivo is likely to provide significant therapeutic benefit in the treatment of cancer, as well as other conditions where angiogenesis is a strong driver to the disease process. During the preclinical safety testing of these drugs, it is becoming increasingly clear that their in vivo efficacy is reflected in the profile of "expected toxicity" (resulting from pharmacology) observed in laboratory animals, so much so, that this profile of "desired" toxicity may act as a signature for their anti-angiogenic effect. In this article we review the major mechanisms controlling angiogenesis and its role during endochondral ossification. We also review the effects of perturbation of endochondral ossification through four mechanisms-inhibition of vascular endothelial growth factor (VEGF), pp60 c-Src kinase and matrix metalloproteinases as well as disruption of the blood supply with vascular targeting agents. Inhibition through each of these mechanisms appears to have broadly similar effects on the epiphyseal growth plate characterised by thickening due to the retention of hypertrophic chondrocytes resulting from the inhibition of angiogenesis. In contrast, in the metaphysis there are differing effects reflecting the specific role of these targets at this site.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537292     DOI: 10.1080/01926230600611836

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  22 in total

Review 1.  Head and neck lymphatic tumors and bony abnormalities: a clinical and molecular review.

Authors:  Karthik Balakrishnan; Mark Majesky; Jonathan A Perkins
Journal:  Lymphat Res Biol       Date:  2011       Impact factor: 2.589

2.  Microarray analysis of irradiated growth plate zones following laser microdissection shows later importance of differentially expressed genes during radiorecovery.

Authors:  Meredith R Pritchard; Jason A Horton; Lihini S Keenawinna; Timothy A Damron
Journal:  Cells Tissues Organs       Date:  2010-07-08       Impact factor: 2.481

3.  Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.

Authors:  Stephan D Voss; Julia Glade-Bender; Sheri L Spunt; Steven G DuBois; Brigitte C Widemann; Julie R Park; Sarah E S Leary; Marvin D Nelson; Peter C Adamson; Susan M Blaney; Brenda Weigel
Journal:  Pediatr Blood Cancer       Date:  2014-09-24       Impact factor: 3.167

Review 4.  Regenerative Medicine Approaches for the Treatment of Pediatric Physeal Injuries.

Authors:  Nichole Shaw; Christopher Erickson; Stephanie J Bryant; Virginia L Ferguson; Melissa D Krebs; Nancy Hadley-Miller; Karin A Payne
Journal:  Tissue Eng Part B Rev       Date:  2017-09-28       Impact factor: 6.389

5.  Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.

Authors:  Timothy P Burkholder; Joshua R Clayton; Mark E Rempala; James R Henry; John M Knobeloch; David Mendel; Johnathan A McLean; Yan Hao; David A Barda; Eileen L Considine; Mark T Uhlik; Yuefeng Chen; Liandong Ma; Laura J Bloem; Jacqueline K Akunda; Denis J McCann; Manuel Sanchez-Felix; David K Clawson; Michael M Lahn; James J Starling
Journal:  Invest New Drugs       Date:  2011-03-01       Impact factor: 3.850

6.  Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials.

Authors:  AeRang Kim; Eva Dombi; Jeffrey Solomon; Elizabeth Fox; Frank M Balis; Brigitte C Widemann
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

Review 7.  Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors:  Maya B Lodish
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

Review 8.  Nonproliferative and Proliferative Lesions of the Rat and Mouse Skeletal Tissues (Bones, Joints, and Teeth).

Authors:  Stacey Fossey; John Vahle; Philip Long; Scott Schelling; Heinrich Ernst; Rogely Waite Boyce; Jacquelin Jolette; Brad Bolon; Alison Bendele; Matthias Rinke; Laura Healy; Wanda High; Daniel Robert Roth; Michael Boyle; Joel Leininger
Journal:  J Toxicol Pathol       Date:  2016-07-29       Impact factor: 1.628

Review 9.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

Authors:  Mark W Kieran; Raghu Kalluri; Yoon-Jae Cho
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

10.  Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway.

Authors:  K D Evans; A M Oberbauer
Journal:  Open Orthop J       Date:  2009-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.